Thermo Fisher Scientific Inc. (TMO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TMO SEC filings page.
Thermo Fisher Scientific Inc. (TMO) reported $46.3B in revenue over the twelve months to Jun 27, 2026, up 7.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Thermo Fisher’s dominant mechanic is durable operating profitability paired with heavier capital demands and less consistent cash conversion.
In FY2025, cash conversion was 1.2x, down from 1.4x in FY2024, showing that reported earnings translated into operating cash less efficiently. Reinvestment pressure compounded that change: free cash flow fell to$6.3B from$7.3B even as capital spending increased, leaving less internally generated cash after reinvestment.
Operating margin recovered from
Total assets reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Thermo Fisher Scientific Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Thermo Fisher Scientific Inc. has an operating margin of 17.4%, meaning the company retains $17 of operating profit per $100 of revenue. This strong profitability earns a score of 81/100, reflecting efficient cost management and pricing power. This is up from 17.1% the prior year.
Thermo Fisher Scientific Inc.'s revenue grew a modest 3.9% year-over-year to $44.6B. This slow but positive growth earns a score of 38/100.
Thermo Fisher Scientific Inc. has elevated debt relative to equity (D/E of 0.67), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 26/100, reflecting increased financial risk.
Thermo Fisher Scientific Inc.'s current ratio of 1.89 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.
Thermo Fisher Scientific Inc. converts 14.1% of revenue into free cash flow ($6.3B). This strong cash generation earns a score of 79/100.
Thermo Fisher Scientific Inc. earns a strong 12.6% return on equity (ROE), meaning it generates $13 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 68/100. This is down from 12.8% the prior year.
Thermo Fisher Scientific Inc. scores 3.91, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($225.5B) relative to total liabilities ($56.9B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Thermo Fisher Scientific Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Thermo Fisher Scientific Inc. generates $1.16 in operating cash flow ($7.8B OCF vs $6.7B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Thermo Fisher Scientific Inc. earns $5.46 in operating income for every $1 of interest expense ($7.7B vs $1.4B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Thermo Fisher Scientific Inc. generated $12.0B in revenue in Q2 2026. This represents an increase of 10.5% from the same quarter a year earlier. Against the prior quarter it is up 9.0%.
Thermo Fisher Scientific Inc.'s EBITDA was $2.9B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.2% from the same quarter a year earlier. Against the prior quarter it is up 11.7%.
Thermo Fisher Scientific Inc. reported $1.7B in net income in Q2 2026. This represents an increase of 7.4% from the same quarter a year earlier. Against the prior quarter it is up 5.1%.
Thermo Fisher Scientific Inc. earned $4.68 per diluted share (EPS) in Q2 2026. This represents an increase of 9.3% from the same quarter a year earlier. Against the prior quarter it is up 5.6%.
Cash & Balance Sheet
Thermo Fisher Scientific Inc. generated $1.7B in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 51.6% from the same quarter a year earlier. Against the prior quarter it is up 105.3%.
Thermo Fisher Scientific Inc. held $4.1B in cash against $39.2B in long-term debt as of Q2 2026.
Thermo Fisher Scientific Inc. paid $0.47 per share in dividends in Q2 2026. This represents an increase of 9.3% from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Thermo Fisher Scientific Inc.'s operating margin was 17.4% in Q2 2026, reflecting core business profitability. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Thermo Fisher Scientific Inc.'s net profit margin was 14.5% in Q2 2026, showing the share of revenue converted to profit. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.5 percentage points.
Thermo Fisher Scientific Inc.'s ROE was 3.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Not reported for Q2 2026.
Capital Allocation
Thermo Fisher Scientific Inc. invested $364.0M in research and development in Q2 2026. This represents an increase of 3.4% from the same quarter a year earlier. Against the prior quarter it is up 8.3%.
Thermo Fisher Scientific Inc. spent $1.0B on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 66.7%.
Thermo Fisher Scientific Inc. invested $450.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 53.1% from the same quarter a year earlier. Against the prior quarter it is up 19.7%.
TMO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0B+10.5% | $11.0B+6.2% | $12.2B+7.2% | $11.1B+4.9% | $10.9B+3.0% | $10.4B+0.2% | $11.4B+4.7% | $10.6B+0.2% |
| R&D Expenses | $364.0M+3.4% | $336.0M-1.8% | $357.0M-4.5% | $346.0M0.0% | $352.0M+3.8% | $342.0M+3.3% | $374.0M+14.4% | $346.0M+8.5% |
| SG&A Expenses | $2.3B+9.0% | $2.2B+5.0% | $2.4B+6.8% | $2.2B+3.1% | $2.1B+1.4% | $2.1B-4.8% | $2.2B+3.3% | $2.1B+2.4% |
| Operating Income | $2.1B+13.8% | $1.9B+8.6% | $2.3B+11.9% | $1.9B+5.6% | $1.8B+0.8% | $1.7B+3.2% | $2.0B+8.7% | $1.8B-1.4% |
| EBITDA | $2.9B+15.2% | $2.6B+7.4% | $3.0B+8.1% | $2.6B+1.0% | $2.5B-3.4% | $2.4B-3.1% | $2.8B+2.4% | $2.6B-5.1% |
| Interest Expense | N/A | $354.0M+16.8% | $365.0M+15.1% | $347.0M-2.5% | $404.0M+14.1% | $303.0M-16.5% | $317.0M-18.7% | $356.0M-0.8% |
| Income Tax | $167.0M+81.5% | $70.0M-26.3% | $153.0M+2.7% | $207.0M+109.1% | $92.0M-28.1% | $95.0M-66.2% | $149.0M+12.0% | $99.0M+86.8% |
| Net Income | $1.7B+7.4% | $1.7B+9.6% | $2.0B+8.3% | $1.6B-0.9% | $1.6B+4.5% | $1.5B+13.2% | $1.8B+13.9% | $1.6B-3.8% |
| EPS (Basic) | $4.68+9.3% | $4.44+11.3% | $5.22+9.0% | $4.28+0.5% | $4.28+5.7% | $3.99+15.0% | $4.79+13.8% | $4.26-4.1% |
| EPS (Diluted) | $4.68+9.3% | $4.43+11.3% | $5.21+9.0% | $4.27+0.5% | $4.28+5.9% | $3.98+15.0% | $4.78+13.8% | $4.25-3.8% |
| Diluted Shares (Avg) | 371M-1.9% | 373M-1.6% | N/A | 378M-1.6% | 378M-1.3% | 379M-1.3% | N/A | 384M-1.0% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TMO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $113.2B+11.8% | $113.3B+14.4% | $110.3B+13.4% | $103.0B+2.6% | $101.2B+2.8% | $99.0B+2.0% | $97.3B-1.4% | $100.4B+3.4% |
| Current Assets | $23.4B-5.0% | $22.3B-4.5% | $28.7B+29.7% | $22.3B-6.3% | $24.6B-3.5% | $23.4B-1.1% | $22.1B-10.0% | $23.8B+3.0% |
| Cash & Equivalents | $4.1B-11.2% | $3.3B-21.3% | $9.9B+145.7% | $2.0B-57.3% | $4.6B-35.3% | $4.1B-24.8% | $4.0B-50.4% | $4.6B-24.5% |
| Short-Term Investments | $0-100.0% | $2.0M-99.9% | $253.0M-83.8% | $1.6B-21.8% | $1.8B+3.7% | $1.8B+3.5% | $1.6B+51933.3% | $2.0B |
| Inventory | $5.6B+1.2% | $5.5B+5.2% | $5.4B+9.0% | $5.7B+5.8% | $5.6B+6.9% | $5.2B+1.8% | $5.0B-2.2% | $5.4B+0.5% |
| Accounts Receivable | $9.5B+10.0% | $9.2B+8.9% | $8.9B+8.7% | $8.9B+7.9% | $8.6B+8.2% | $8.5B+6.6% | $8.2B-0.4% | $8.3B-1.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $54.8B+16.0% | $55.2B+18.7% | $49.4B+7.7% | $49.3B+5.5% | $47.2B+7.8% | $46.5B+6.0% | $45.9B+4.2% | $46.7B+7.2% |
| Total Liabilities | $60.5B+19.3% | $61.3B+23.6% | $56.9B+19.3% | $52.0B+1.2% | $50.7B-0.7% | $49.7B-3.7% | $47.7B-8.2% | $51.4B-0.7% |
| Current Liabilities | $15.1B+18.5% | $14.6B+11.0% | $15.2B+13.9% | $14.9B+2.0% | $12.7B-13.9% | $13.2B-5.5% | $13.3B-4.9% | $14.6B+3.1% |
| Non-Current Liabilities | $45.4B+19.5% | $46.7B+28.1% | $41.7B+21.3% | $37.1B+0.9% | $38.0B+4.7% | $36.5B-3.1% | $34.4B-9.4% | $36.8B-2.1% |
| Long-Term Debt | $39.2B+18.7% | $40.1B+27.7% | $35.9B+23.4% | $31.9B+2.1% | $33.0B+9.0% | $31.4B+0.7% | $29.1B-7.2% | $31.2B+2.3% |
| Total Equity | $52.7B+4.3% | $51.9B+5.2% | $53.4B+7.7% | $51.0B+4.1% | $50.5B+6.5% | $49.4B+8.5% | $49.6B+6.1% | $49.0B+8.1% |
| Retained Earnings | $62.2B+11.3% | $60.6B+11.4% | $59.2B+11.4% | $57.4B+11.5% | $55.9B+11.9% | $54.4B+12.2% | $53.1B+12.1% | $51.4B+12.1% |
TMO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.1B+51.9% | $1.2B+64.9% | $3.5B+5.1% | $2.2B+3.4% | $1.4B-28.6% | $723.0M-42.2% | $3.3B-11.6% | $2.2B-10.3% |
| Depreciation & Amortization | $816.0M+19.0% | $736.0M+4.4% | $728.0M-1.9% | $662.0M-10.5% | $686.0M-13.2% | $705.0M-15.7% | $742.0M-11.6% | $740.0M-13.2% |
| Stock-Based Compensation | N/A | $83.0M+10.7% | N/A | N/A | N/A | $75.0M+7.1% | N/A | N/A |
| Capital Expenditures | $450.0M+53.1% | $376.0M+3.9% | $465.0M-3.1% | $404.0M+48.5% | $294.0M-2.3% | $362.0M+4.3% | $480.0M+18.5% | $272.0M-18.1% |
| Free Cash Flow | $1.7B+51.6% | $816.0M+126.0% | $3.0B+6.5% | $1.8B-3.1% | $1.1B-33.4% | $361.0M-60.1% | $2.8B-15.3% | $1.9B-9.0% |
| Investing Cash Flow | $164.0M+156.9% | -$9.0B-1600.4% | $891.0M+4355.0% | -$4.1B-15.2% | -$288.0M-13.8% | -$527.0M+74.0% | $20.0M+105.3% | -$3.6B-203.0% |
| Financing Cash Flow | -$1.6B-58.5% | $1.1B+1171.6% | $3.5B+196.2% | -$632.0M+46.9% | -$991.0M-761.7% | -$102.0M+94.4% | -$3.7B-156.7% | -$1.2B-164.2% |
| Dividends Paid | $175.0M+8.0% | $162.0M+8.7% | $162.0M+8.7% | $163.0M+8.7% | $162.0M+8.7% | $149.0M+10.4% | $149.0M+9.6% | $150.0M+11.1% |
| Share Buybacks | $1.0B | $3.0B+50.0% | $37.0M-96.3% | $963.0M | $0 | $2.0B-33.3% | $1.0B | $0 |
TMO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.4%+0.5pp | 16.9%+0.4pp | 18.5%+0.8pp | 17.4%+0.1pp | 16.9%-0.4pp | 16.6%+0.5pp | 17.7%+0.7pp | 17.3%-0.3pp |
| Net Margin | 14.5%-0.4pp | 15.0%+0.5pp | 16.2%+0.2pp | 14.5%-0.8pp | 14.9%+0.2pp | 14.5%+1.7pp | 16.1%+1.3pp | 15.4%-0.7pp |
| Return on Equity | 3.3%+0.1pp | 3.2%+0.1pp | 3.7%0.0pp | 3.2%-0.2pp | 3.2%-0.1pp | 3.0%+0.1pp | 3.7%+0.3pp | 3.3%-0.4pp |
| Return on Assets | 1.5%-0.1pp | 1.5%-0.1pp | 1.8%-0.1pp | 1.6%-0.1pp | 1.6%0.0pp | 1.5%+0.1pp | 1.9%+0.3pp | 1.6%-0.1pp |
| Current Ratio | 1.55-0.4x | 1.53-0.2x | 1.89+0.2x | 1.50-0.1x | 1.93+0.2x | 1.77+0.1x | 1.66-0.1x | 1.630.0x |
| Debt-to-Equity | 0.74+0.1x | 0.77+0.1x | 0.67+0.1x | 0.620.0x | 0.650.0x | 0.640.0x | 0.59-0.1x | 0.640.0x |
| Asset Turnover | 0.110.0x | 0.100.0x | 0.110.0x | 0.110.0x | 0.110.0x | 0.100.0x | 0.120.0x | 0.110.0x |
| FCF Margin | 14.0%+3.8pp | 7.4%+3.9pp | 24.5%-0.2pp | 16.5%-1.4pp | 10.2%-5.6pp | 3.5%-5.3pp | 24.7%-5.8pp | 17.9%-1.8pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. TMO | FY2025 | $44.6B | $6.7B | 15.1% | $225.5B | 58/100 |
| Danaher Corporation DHR | FY2025 | $24.6B | $3.6B | 14.7% | $144.0B | 60/100 |
| Idexx Laboratories Inc IDXX | FY2025 | $4.3B | $1.1B | 24.6% | $39.9B | 76/100 |
| Agilent Technologies Inc. A | FY2025 | $6.9B | $1.3B | 18.8% | $40.8B | 67/100 |
| Mettler-Toledo International MTD | FY2025 | $4.0B | $869.2M | 21.6% | $25.7B | 27/100 |
Where Thermo Fisher Scientific Inc. Ranks
Frequently Asked Questions
What is Thermo Fisher Scientific Inc.'s annual revenue?
Thermo Fisher Scientific Inc. (TMO) reported $44.6B in total revenue for fiscal year 2025. This represents a 3.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Thermo Fisher Scientific Inc.'s revenue growing?
Thermo Fisher Scientific Inc. (TMO) revenue grew by 3.9% year-over-year, from $42.9B to $44.6B in fiscal year 2025.
Is Thermo Fisher Scientific Inc. profitable?
Yes, Thermo Fisher Scientific Inc. (TMO) reported a net income of $6.7B in fiscal year 2025, with a net profit margin of 15.1%.
What is Thermo Fisher Scientific Inc.'s EBITDA?
Thermo Fisher Scientific Inc. (TMO) had EBITDA of $10.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Thermo Fisher Scientific Inc. have?
As of fiscal year 2025, Thermo Fisher Scientific Inc. (TMO) had $9.9B in cash and equivalents against $35.9B in long-term debt.
What is Thermo Fisher Scientific Inc.'s operating margin?
Thermo Fisher Scientific Inc. (TMO) had an operating margin of 17.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Thermo Fisher Scientific Inc.'s net profit margin?
Thermo Fisher Scientific Inc. (TMO) had a net profit margin of 15.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Thermo Fisher Scientific Inc. pay dividends?
Yes, Thermo Fisher Scientific Inc. (TMO) paid $1.72 per share in dividends during fiscal year 2025.
What is Thermo Fisher Scientific Inc.'s return on equity (ROE)?
Thermo Fisher Scientific Inc. (TMO) has a return on equity of 12.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Thermo Fisher Scientific Inc.'s free cash flow?
Thermo Fisher Scientific Inc. (TMO) generated $6.3B in free cash flow during fiscal year 2025. This represents a -13.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Thermo Fisher Scientific Inc.'s operating cash flow?
Thermo Fisher Scientific Inc. (TMO) generated $7.8B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Thermo Fisher Scientific Inc.'s total assets?
Thermo Fisher Scientific Inc. (TMO) had $110.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Thermo Fisher Scientific Inc.'s capital expenditures?
Thermo Fisher Scientific Inc. (TMO) invested $1.5B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Thermo Fisher Scientific Inc. spend on research and development?
Thermo Fisher Scientific Inc. (TMO) invested $1.4B in research and development during fiscal year 2025.
What is Thermo Fisher Scientific Inc.'s current ratio?
Thermo Fisher Scientific Inc. (TMO) had a current ratio of 1.89 as of fiscal year 2025, which is generally considered healthy.
What is Thermo Fisher Scientific Inc.'s debt-to-equity ratio?
Thermo Fisher Scientific Inc. (TMO) had a debt-to-equity ratio of 0.67 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Thermo Fisher Scientific Inc.'s return on assets (ROA)?
Thermo Fisher Scientific Inc. (TMO) had a return on assets of 6.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Thermo Fisher Scientific Inc.'s P/E ratio?
Thermo Fisher Scientific Inc. (TMO) trades at 32.3x earnings, its market capitalization divided by net income of $7.0B net income, trailing 12 months to June 27, 2026. The market capitalization is $225.5B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Thermo Fisher Scientific Inc.'s price-to-sales ratio?
Thermo Fisher Scientific Inc. (TMO) trades at 4.9x sales, its market capitalization divided by revenue of $46.3B revenue, trailing 12 months to June 27, 2026. The market capitalization is $225.5B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Thermo Fisher Scientific Inc.'s Altman Z-Score?
Thermo Fisher Scientific Inc. (TMO) has an Altman Z-Score of 3.91, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Thermo Fisher Scientific Inc.'s Piotroski F-Score?
Thermo Fisher Scientific Inc. (TMO) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Thermo Fisher Scientific Inc.'s earnings high quality?
Thermo Fisher Scientific Inc. (TMO) has an earnings quality ratio of 1.16x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Thermo Fisher Scientific Inc. cover its interest payments?
Thermo Fisher Scientific Inc. (TMO) has an interest coverage ratio of 5.46x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Thermo Fisher Scientific Inc.?
Thermo Fisher Scientific Inc. (TMO) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.